10x Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 02, 2023 at 04:05 pm EDT
Share
10x Genomics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 153.64 million compared to USD 131.07 million a year ago. Net loss was USD 92.99 million compared to USD 41.91 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to USD 0.37 a year ago.
For the nine months, sales was USD 434.75 million compared to USD 360.18 million a year ago. Net loss was USD 206.15 million compared to USD 148.79 million a year ago. Basic loss per share from continuing operations was USD 1.77 compared to USD 1.31 a year ago.
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
10X GENOMICS, INC. 
